Main Navigation

Quick Links

Startup news: The latest out of Blackrock Neurotech, Recursion Pharmaceuticals and Salarius Pharmaceuticals

University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:

EY announces Marcus Gerhardt and Florian Solzbacher of Blackrock Neurotech as Entrepreneur Of The Year® 2023 Mountain West Award Finalists

Blackrock Neurotech logo

Ernst & Young LLP (EY US) announced that Marcus Gerhardt, co-founder and CEO, and Florian Solzbacher, co-founder and President, of Blackrock Neurotech were named Entrepreneur Of The Year® 2023 Mountain West Award finalists. Now in its 37th year, Entrepreneur Of The Year is one of the preeminent competitive business awards for transformative entrepreneurs and leaders of high-growth companies who are building a more equitable, sustainable and prosperous world for all.

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

Recursion logo

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.

Recursion CEO Chris Gibson named one of Fierce Pharma’s most influential people in biopharma in 2023

Recursion logo

The times are changing in biopharma. With the top drugmakers no longer committing most of their resources to the pandemic, biopharma is returning to its roots. But it’s clear the world is quickly changing, and so too are the companies that make up our industry.

At the University of Utah, Chris Gibson was studying to become a physician-scientist and considering a career in R&D where he would search for medicines to cure serious diseases. He is now CEO of one of the industry’s most promising biotechs.

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Logo

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that the U.S. Food and Drug Administration (FDA) has removed its partial clinical hold on Salarius’ Phase 1/2 Ewing sarcoma clinical trial evaluating seclidemstat, Salarius’ novel oral, reversible, targeted LSD1 inhibitor.

Oh, hello!

Contact Form